Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial ...

Amicus (FOLD) is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The ...

Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Travere Therapeutics (TVTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...